Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Introducing Products
    • Child-friendly medicines
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

Partners

TB Alliance works with a diverse network of global partners, including the world’s leading pharmaceutical developers, academic institutions, and research institutes. The following organizations are TB Alliance research and development partners.

  • AbbVie
  • Astellas
  • Bill & Melinda Gates Medical Research Institute
  • Chugai
  • Daiichi Sankyo RD Novare
  • Eli Lilly
  • Evotec
  • Foundation for Neglected Disease Research
  • Fujifilm
  • GlaxoSmithKline
  • Global Health Drug Discovery Institute
  • Harvard University
  • HyphaGenesis
  • IMPAACT
  • Institute of Materia Medica
  • Johns Hopkins University
  • Macleods
  • Medical Research Council at University College London
  • Merck
  • National Institutes of Health
  • PanACEA
  • Schrodinger
  • Stellenbosch University
  • Takeda Pharmaceuticals
  • TB Drug Accelerator Program
  • University College London
  • University of Auckland
  • University of Auckland
  • University of Illinois at Chicago
  • Yonsei University
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis
Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis
TB Medicine Pretomanid Enters Regulatory Review Process in the United States

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2019 The TB Alliance. All Rights Reserved. Site by Darby Communications